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Abstract
Background: An imbalance in the inflammatory tumor necrosis factor system, including soluble tumor necrosis factor 
receptor 2 (sTNFR2), may contribute to the pathophysiology of schizophrenia.
Methods: We measured the plasma levels of sTNFR2 in 256 healthy controls and 250 patients with schizophrenia including 
antipsychotic drug-free patients and treatment-resistant patients. We also explored the possible association between 
plasma sTNFR2 levels and cognitive performance in healthy controls and patients with schizophrenia using the Wechsler 
Adult Intelligence Scale, Third Edition, the Wechsler Memory Scale-Revised, and the Rey Auditory Verbal Learning Test. An 
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Results: We found that the plasma levels of sTNFR2 were significantly higher in patients with schizophrenia, including both 
antipsychotic drug-free patients and treatment-resistant patients. We found a significant negative association between 
plasma sTNFR2 levels and cognitive performance in controls and patients with schizophrenia. Hippocampal volume was also 
negatively associated with plasma sTNFR2 levels in patients with schizophrenia.
Conclusion: Together, these convergent data suggest a possible biological mechanism for schizophrenia, whereby increased 
sTNFR2 levels are associated with a smaller hippocampal volume and cognitive impairment.
Keywords: soluble tumor necrosis factor receptor 2, cognitive performance, hippocampal volume
Introduction
Increasing evidence has indicated that inflammation may play 
a critical role in the pathophysiology of schizophrenia (Monji 
et al., 2009; Dean et al., 2013; Na et al., 2014; Hung et al., 2017). 
Tumor necrosis factor-α (TNF-α) is a proinflammatory cytokine 
involved in the innate immune response. TNF-α and the down-
stream TNF-α signaling pathways of 2 distinct membrane-bound 
receptors, soluble tumor necrosis factor receptor 1 (sTNFR1) and 
soluble tumor necrosis factor receptor 2 (sTNFR2), play crit-
ical roles in brain function, including neurotransmission, syn-
apse formation, and neurogenesis (McCoy and Tansey, 2008). 
sTNFR1 and sTNFR2 are differentially expressed and controlled; 
sTNFR1 is historically thought to promote apoptosis and cyto-
toxicity, while cell survival, proliferation, and protective cellular 
responses induced by TNF-α are attributed primarily to sTNFR2 
(Montgomery and Bowers, 2012). Depletion of sTNFR2, but not 
sTNFR1, has been reported to lead to hippocampal neuron death 
through different signal transduction pathways than those of 
sTNFR1 (Yang et  al., 2002), suggesting that sTNFR2 plays pro-
tective roles in hippocampal neurons. Protective roles of sTNFR2 
signaling were also reported in individuals with neurodegenera-
tive disorders, including Alzheimer’s disease (Shen et al., 1997). 
Several studies have demonstrated that patients with schizo-
phrenia have increased peripheral levels of sTNFR2 (Coelho 
et al., 2008; Noto et al., 2013; Hoseth et al., 2017). We also previ-
ously reported that patients with schizophrenia have increased 
levels of plasma sTNFR2 (Yamamori et al., 2016). Together, these 
findings indicate that sTNFR2 might be involved in the patho-
physiology of schizophrenia.
Many studies have reported that patients with schizophre-
nia demonstrate smaller hippocampal volumes (Okada et  al., 
2016) and cognitive decline (Hashimoto et al., 2013; Fujino et al., 
2014, 2016; Ohi et  al., 2015) than those without. Elevated per-
ipheral proinflammatory cytokines are reported to negatively 
affect both hippocampal structure and cognitive function-
ing. Higher peripheral sTNFR2 levels were also reported to be 
associated with smaller hippocampal volume in a community 
sample (Schmidt et al., 2016), as well as with poorer cognitive 
test scores in a community-living aged population (Gao et al., 
2016), in Parkinson’s disease patients (Rocha et  al., 2014), and 
in mood disorder patients (Doganavsargil-Baysal et  al., 2013; 
Bobińska et  al., 2017). However, the correlations between per-
ipheral sTNFR2 levels and hippocampal structure and cognitive 
functioning have not been thoroughly investigated in patients 
with schizophrenia.
We hypothesized that sTNFR2 are elevated as compensa-
tory response to proinflammatory imbalance in the TNF sys-
tem and play protective roles to prevent hippocampal volume 
loss in schizophrenia. The aim of this study was to investigate 
the plasma levels of sTNFR2 in patients with schizophrenia in 
a large Japanese cohort that included antipsychotic drug-free 
patients and treatment-resistant patients. We further investi-
gated the possible association between plasma levels of sTNFR2 




A total of 250 patients with schizophrenia and 256 healthy 
controls were included in this study. The patients and healthy 
controls were age and gender matched (Table  1). Blood sam-
ples were collected, and plasma was used for the analysis. Most 
cases were recruited at the Osaka University Hospital. One set of 
Osaka samples of 40 patients with schizophrenia and 40 healthy 
controls are the same samples used in the previous study that 
showed a significant increase of plasma sTNFR2 in patients 
with schizophrenia (Yamamori et  al., 2016). In all, 80 patients 
with schizophrenia and 80 healthy controls were recruited at 
Chiba University Hospital and Tokushima University Hospital. 
Each subject had been diagnosed and assessed by at least 2 
trained psychiatrists according to the Diagnostic and Statistical 
Manual of Mental Disorders, Fourth Edition (DSM-IV), criteria 
based on a structured clinical interview for DSM-IV axis I dis-
orders (SCID-I). Symptoms of schizophrenia were assessed with 
the Positive and Negative Syndrome Scale (PANSS). The total of 
prescribed antipsychotics was calculated using chlorpromazine 
(CPZ) equivalents (mg/d) (Inada and Inagaki, 2015). Patients with 
Significance Statement
The tumor necrosis factor (TNF) system, including soluble tumor necrosis factor receptor 2 (sTNFR2), might be involved in the 
pathophysiology of schizophrenia. We found that the plasma levels of sTNFR2 were significantly higher in patients with schizo-
phrenia, including antipsychotic drug-free patients. As far as we know, this is the first study to demonstrate that plasma sTNFR2 
levels are significantly increased in antipsychotic drugs-free patients with schizophrenia. sTNFR2 are reported to negatively 
affect both hippocampal structure and cognitive functioning. However, the correlations between sTNFR2 levels and hippocampal 
structure and cognitive functioning have not been thoroughly investigated in patients with schizophrenia. We found a significant 
negative association between plasma sTNFR2 levels and cognitive performance in controls and patients with schizophrenia. 
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comorbidities of substance-related disorders or mental retard-
ation were excluded. The “drug-free” patients took no antip-
sychotics for over 1 week. “Treatment-resistant” was defined 
according to the following criteria mentioned in CPZ drug infor-
mation in JAPAN: (1) non- or little response to treatment from 
at least 2 adequately dosed antipsychotic trials for at least 4 
weeks (including at least 1 second-generation antipsychotic, 
>600 mg/d of CPZ equivalent) and patients never had the Global 
Assessment of Functioning scores >40. (2) Intolerance to at 
least 2 second-generation antipsychotics because of uncon-
trolled extrapyramidal symptoms. All subjects included in this 
study met the criteria of non- or little response. Controls were 
recruited through local advertisements. Psychiatrically, medic-
ally, and neurologically healthy controls were evaluated via the 
DSM-IV structured clinical interview, nonpatient version that 
included the interview whether the subject has physical prob-
lems. Subjects were excluded if they had neurological or med-
ical conditions that could potentially affect the central nervous 
system, such as an atypical headache, head trauma with loss 
of consciousness, chronic lung disease, kidney disease, chronic 
hepatic disease, thyroid disease, active stage cancer, cerebro-
vascular disease, epilepsy, or seizures. Neurological and med-
ical conditions were assessed mainly by interview. In the case 
of patients, blood tests were also conducted to confirm med-
ical conditions. Written informed consent was obtained from 
all subjects after the procedures had been fully explained. This 
study was conducted in accordance with the World Medical 
Association’s Declaration of Helsinki and was approved by 
the Research Ethical Committee of Osaka University, Chiba 
University and Tokushima University.
Determination of Plasma sTNFR2 Levels
Plasma levels of sTNFR2 were determined with Quantikine 
human ELISA kits from R&D Systems. According to the manu-
facturer’s instructions in the ELISA kits, the intra-assay and 
inter-assay CVs for the sTNFR2 ELISAs, as measured in 20 
plasma samples, averaged 3.5% and 4.1%, respectively. The min-
imum detectable dose of human sTNF2 was 0.6 pg/mL, and all 
values obtained from our plasma samples were above the mini-
mum detectable dose. All plasma samples were sent to Chiba 
University, and the plasma levels of sTNFR2 were measured in 
Chiba University.
Imaging Processing
All MRI data were sent to National Institute for Physiological 
Sciences, and FreeSurfer analysis was done in National Institute 
for Physiological Sciences. Among the subjects, 167 healthy 
subjects and 94 patients with schizophrenia underwent MRI. 
MRI data were obtained using one of the following 3 scan-
ners: (1) 1.5T GE Signa EXCITE system; (2) 3.0T GE Signa HDxt; 
(3) 3.0T GE MR750. A 3-dimensional volumetric acquisition of a 
T1-weighted gradient echo sequence produced a gapless series 
of sagittal sections using a spoiled gradient-recalled acquisition 
in the steady-state sequence. The sequence parameters for each 
scanner were as follows: (1) 1.5T GE Signa EXCITE: number of 
slices, 124; TE/TR, 4.2/12.6 ms; flip angle, 15°; acquisition matrix, 
256 × 256; 1NEX, FOV, 24 × 24 cm; and slice thickness, 1.4 mm; (2) 
3.0T GE Signa HDxt: number of slices, 172; TE/TR, 2.9/7.2 ms; flip 
angle, 11°; acquisition matrix, 256 × 256; 1NEX, FOV, 24 × 24 cm; 
and slice thickness, 1 mm; and (3) 3.0T GE MR 750: number of 
slices, 156; TE/TR, 3.1/8.2 ms; flip angle, 11°; acquisition matrix, 
256 × 256; 1NEX, FOV, 24 × 24  cm; and slice thickness, 1.2  mm. 
Original T1-weighted images were checked by visual inspec-
tion. We excluded images with insufficient brain coverage (field-
of-view problem), those with low signal-to-noise ratios or any 
artifacts (e.g., motion artifacts and magnetic susceptibility arti-
facts), and those with any abnormal organic findings (e.g., large 
cerebellar cysts and cavum septum pellucidum).
T1-weighted imaging data of 153 healthy subjects and 82 
patients with schizophrenia were processed with FreeSurfer 
5.3 software (http://surfer.nmr.mgh.harvard.edu), as described 
previously (van Erp et  al., 2016). Through this procedure, we 
obtained images of subcortical segmentation and regional vol-
umes (for the bilateral lateral ventricles, thalamus, caudate, 
putamen, globus pallidus, hippocampus, amygdala, accumbens, 
and the ICV), and left hippocampal volume data were used to 
assess the reproducibility of the association with plasma levels 
of sTNFR2.
Assessment of Cognitive Functions
Cognitive function was assessed with the Wechsler Adult 
Intelligence Scale, Third Edition (WAIS-III) (Wechsler, 1997; 
Committee, 2006), the Wechsler Memory Scale-Revised (WMS-
R) (Wechsler, 1987), and the Rey Auditory Verbal Learning Test 
(AVLT). The numbers of subjects who underwent testing with 
the WAIS-III, WMS-R, and AVLT are shown in Table 3.
Statistical Analysis
The statistical analysis was performed with SPSS 20.0 soft-
ware for Windows (SPSS Japan Inc). Variables were expressed as 
the mean ± SD. Data normality was assessed via Kolmogorov-
Smirnov and Shapiro-Wilk tests, and the plasma sTNFR2 lev-
els did not show a Gaussian distribution. Differences in clinical 
characteristics between patients and controls were analyzed 
using χ2 tests for categorical variables and the Mann–Whitney 
U-test for continuous variables. The groups did not differ with 
respect to age or gender (P > .05). Differences in the plasma lev-
els of sTNFR2, cognitive and memory functions, and hippocam-
pal volume between the patients and controls were analyzed 
via the Mann-Whitney U-test. Correlations were examined with 
Spearman’s rank correlation. Potential confounders of plasma 
sTNFR2 (age, sex, smoking status) were investigated with non-
parametric tests (Mann-Whitney U-test and Spearman’s rank 
correlation), and the P values of these confounders were <.05. 
These confounders were controlled using partial correlations. 
In the analysis of patients with schizophrenia, CPZ dose was 
also controlled. The Bonferroni correction was used for multiple 
comparison corrections. Differences were considered statisti-
cally significant for P  < .05.
The MR images were processed with SPM12 (Wellcome 
Department of imaging Neuroscience, University College 
London, UK, http://www.fil.ion.ucl.ac.uk/spm) in MATLAB R2015b 
(The Mathworks, Natick, MA, USA) for tissue segmentation and 
anatomical normalization using the diffeomorphic anatomi-
cal registration through an exponentiated lie algebra (DARTEL) 
algorithm. Custom DARTEL templates were generated from all 
participants’ gray matter and white matter images. After spa-
tial normalization, the gray matter images were modulated to 
preserve the volume, followed by smoothing with an 8-mm full 
width at half maximum Gaussian kernel. For this preprocessing, 
default parameters were used. In addition, the total intracranial 
volume was calculated by summing up the gray matter volume, 
white matter volume, and cerebrospinal fluid volume using 
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covariates, we used a multiple regression model and explored 
the correlation between the serum level of sTNFR and gray mat-
ter volume, treating age, gender, and total intracranial volume 
as confounding covariates. Since we used images from multi-
ple scanners, scanner site was modeled as a factor as previous 
studies employed (Stonnington et al., 2008). However, since we 
were interested in the correlation between sTNFR2 and grey 
matter, we modified the design matrix so that we could explore 
the correlation accounting for the scanner difference (supple-
mentary Figure  1). Detail is explained in the supplementary 
Information. Beside whole brain analysis, we performed small 
volume correction, since we were interested in cognitive func-
tion, especially memory. For this analysis, we generated a mask 
of bilateral hippocampi using the Neuromorphometrics atlas 
implemented in SPM12. The significance threshold was also set 
to family-wise error corrected P value < .05. At the same time, 
we extracted the volume of whole right and left hippocampus 
using “get_totals” script by Ged Ridgway (http://www0.cs.ucl.
ac.uk/staff/g.ridgway/vbm/get_totals.m_x0001). We employed 
the Neuromorphometric atlas implemented in SPM12 to define 
both left and right hippocampus.
Results
Plasma Levels of sTNFR2
The plasma levels of sTNFR2 were compared between the 
schizophrenia patient group (total n = 250) and the control 
group (total n = 256). Seven sets of samples were investigated, 
including 3 sets of samples from Osaka, 2 sets of samples from 
Tokushima and Chiba, 1 set of antipsychotic drug-free patient 
samples from Osaka, and 1 set of treatment-resistant schizo-
phrenia samples from Osaka (Table 1). All sample sets were age 
and gender matched. In all sets of samples, the plasma levels 
of sTNFR2 were significantly higher in patients than in controls 
(Figure 1; Table 2, Mann-Whitney U-test; z = -8.21, P = 2.3 × 10–16).
sTNFR2 and Cognitive and Memory Function
Cognitive function was investigated using the WAIS-III, and 
memory function was investigated using the WMS-R and AVLT. 
Cognitive and memory functions were compared between the 
schizophrenia patient group and the control group. Data of cog-
nitive and memory functions were available in 3 sets of samples 
from Osaka, 1 set of antipsychotic drug-free patient samples 
from Osaka, and 1 set of treatment-resistant schizophrenia 
samples from Osaka. In all categories of cognitive and memory 
functions, scores were significantly lower in patients than in 
controls (supplementary Table 1b). When we see the difference 
in each drug-free, treatment-resistant, and remaining patients 
with schizophrenia (OSAKA 1–3), and healthy controls, signifi-
cant decline in schizophrenia was observed in all sets of sam-
ples (supplementary Table 1a).
The relationship between plasma sTNFR2 levels and cogni-
tive function was investigated via the WAIS-III. Plasma sTNFR2 
levels were significantly and negatively correlated with the WAIS 
Verbal IQ (VIQ), Performance IQ (PIQ), Full-scale IQ (FIQ) (Fig. 2a), 
Picture Completion Block Design and Matrix Reasoning (PO), and 
Block Design and Matrix Reasoning (PS) in all samples (patients 
with schizophrenia and healthy controls) after Bonferroni cor-
rection (Table 3, VIQ; r = -0.19, P = 2.4 × 10–3, corrected P = .031, PIQ; 
r = -0.21, P = 8.1 × 10–4, corrected P = .011, FIQ; r = -0.22, P = 3.5 × 10–4, 
corrected P = 4.5 × 10–3, PO; r = -0.2, P = 1.5 × 10–3, corrected P = .019, 
PS; r = -0.2, P = 1.0 × 10–3, corrected P = .013). No significant correla-
tion was observed when correlations between sTNFR2 levels and 
cognitive functions assessed via the WAIS-III were investigated 
in patients with schizophrenia or in healthy controls (Table 3). To 
exclude the effects of age, gender, and smoking status, we con-
ducted a partial correlation analysis between the plasma sTNFR2 
levels and cognitive function assessed via WAIS-III using age, 
gender, and smoking status as control variables. In patients with 
schizophrenia, CPZ dose was also controlled. Plasma sTNFR2 
levels were significantly and negatively correlated with VIQ, PIQ, 
FIQ, and all 4 secondary indices of the WAIS-III (VC; Vocabulary, 
Similarities and Information, PO, WM; Arithmetic, Digit Span 
and Letter Number Sequencing, and PS) in all samples (patients 
with schizophrenia and healthy controls) as shown in supple-
mentary Table 2. Then, we see the correlation in each drug-free, 
treatment-resistant, and remaining patients with schizophrenia 
(OSAKA 1–3) and healthy controls. Significant and negative cor-
relation was observed between plasma sTNFR2 levels and FIQ in 
the remaining patients with schizophrenia and healthy controls 
(supplementary Table  3a, FIQ; r = -0.23, P = 2.8 × 10–3, corrected 
P = .04) in all samples (patients with schizophrenia and healthy 
controls).
We also investigated the relationship between the plasma 
sTNFR2 levels and memory functions using the WMS-R and 
AVLT. Plasma sTNFR2 levels were significantly and negatively 
correlated with the WMS-R Verbal Memory (VerM), Visual 
Memory (ViM), and General Memory (GM) subscales (Figure 2b), 
as well as Delayed recall (DR) and total recall in the AVLT in all 
samples (patients with schizophrenia and healthy controls) after 
Bonferroni correction (Table  3; VerM; r = -0.26, P = 1.3 × 10–5, cor-
rected P = 1.7 × 10–4, ViM; r = -0.22, P = 2.2 × 10–4, corrected P = 2.8 × 10–
3, GM; r = -0.28, P = 2.2 × 10–6, corrected P = 2.9 × 10–5, DR; r = -0.26, 
P = 2.2 × 10–5, corrected P = 2.9 × 10–4, AVLT; r = -0.36, P = 2.4 × 10–9, 
corrected P = 3.2 × 10–8). No significant correlations were observed 
between sTNFR2 levels and memory function assessed via the 
WMS-R and AVLT in patients with schizophrenia. In healthy 
Figure 1. The plasma levels of sTNFR2 were measured in healthy controls (HC) 
(n = 256) and schizophrenia (SCZ) patients (n = 250). The bars represent mean val-
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controls, plasma sTNFR2 levels were significantly and nega-
tively correlated with total recall of the AVLT (Table 3; r = -0.32, 
P = 1.2 × 10–5, corrected P = 1.6 × 10–4). To exclude the effects of age, 
gender, and smoking status, we conducted a partial correlation 
analysis between the plasma sTNFR2 levels and memory func-
tions assessed via the WMS-R and AVLT using age, gender, and 
smoking status as control variables. In patients with schizophre-
nia, CPZ dose was also controlled. Plasma sTNFR2 levels were 
significantly and negatively correlated with VerM, ViM, GM, A/C 
(Attention and Concentration), DR, and total recall in the AVLT 
in all samples (patients with schizophrenia and healthy con-
trols) as shown in supplementary Table 2. Plasma sTNFR2 levels 
were significantly and negatively correlated with total recall in 
the AVLT only in healthy controls by partial correlation ana-
lysis using age, gender, and smoking status as control variables 
(supplementary Table  2). Then, we see the correlation in each 
drug-free, treatment-resistant, and remaining patients with 
schizophrenia (OSAKA 1–3) and healthy controls. Significant 
and negative correlation was observed between plasma sTNFR2 
levels and VerM, ViM, GM, DR, and total recall in the AVLT in 
the remaining patients with schizophrenia and healthy con-
trols (supplementary Table  3a, VerM; r = -0.27, P = 2.8 × 10–4, cor-
rected P = 3.7 × 10–3, ViM; r = -0.24, P = 1.3 × 10–3, corrected P = .02, 
GM; r = -0.31, P = 3.2 × 10–5, corrected P = 4.1 × 10–4, DR; r = -0.27, 
P = 3.7 × 10–4, corrected P = 4.8 × 10–3, AVLT; r = -0.42, P = 1.9 × 10–8, 
corrected P = 2.5 × 10–7).
sTNFR2 and Hippocampal Volume
Hippocampal volume was compared between the schizophre-
nia patient group and the control group. Left and right hip-
pocampal volume was assessed by voxel-based morphometry 
(VBM) and FreeSurfer analysis. MRI data were available in 3 sets 
of samples from Osaka, 1 set of antipsychotic drug-free patient 
samples from Osaka, and 1 set of treatment-resistant schizo-
phrenia samples from Osaka. Both left and right hippocampal 
volume were significantly smaller in patients than in controls 
(supplementary Table 4). When we see the difference in each drug-
free, treatment-resistant, and remaining patients with schizo-
phrenia and healthy controls, significant decrease of hippocampal 
volume in schizophrenia was observed in all sets of samples 
(supplementary Table 4).
Whole brain correlational analysis between sTNFR2 and grey 
matter volume by VBM analysis revealed no significant region. 
However, small volume correction revealed negative correl-
ation between sTNFR2 and left hippocampus. (supplementary 
Figure 2, P = .031, family-wise error corrected for multiple com-
parison, k = 28, x = -33, y = -26, z = -9). Since we found significant 
correlation between STNFR2 and a cluster in left hippocampus, 
we investigated the relationships between plasma sTMFR2 lev-
els and left whole hippocampal volume. Plasma sTNFR2 levels 
were significantly and negatively correlated with left whole 
hippocampal volume (patients with schizophrenia and healthy 



















HC (ng/mL) 1.88 ± 0.44 1.68 ± 0.42 1.81 ± 0.37 1.93 ± 0.45 2.01 ± 0.66 2.50 ± 0.64 1.98 ± 0.44 1.97 ± 0.54
SCZ (ng/mL) 2.65 ± 0.89 1.96 ± 0.54 2.46 ± 0.68 2.28 ± 0.66 2.99 ± 0.94 3.57 ± 1.25 2.27 ± 0.60 2.57 ± 0.96
P value 1.9 × 10–4*** .014* 5.1 × 10–7*** .017* 4.7 × 10–4*** 2.5 × 10–6*** .019* 2.3 × 10–16***
Effect size 1.70 0.73 1.29 1.07 2.11 2.68 0.94 1.68
Abbreviations: HC, healthy control; SCZ, schizophrenia.
*P < .05, **P < .01, ***P < .005.
The mean ± SD is shown.
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controls) (Figure  3a, total; n = 261, r = -0.14, P = .02). Anatomical 
atlases from which the signal was extracted are shown in 
Figure  3b. Plasma sTNFR2 levels remained significantly and 
negatively correlated with left hippocampal volume measured 
by VBM analysis only in patients with schizophrenia (SCZ; n = 94, 
r = -0.22, P = .03). No significant correlation was observed between 
sTNFR2 levels and left hippocampal volume in healthy controls 
(HC; n = 167, r = -0.04, P = .61). To exclude the effects of age, gender, 
and smoking status, we conducted a partial correlation analysis 
between the plasma sTNFR2 levels and left hippocampal vol-
ume using age, gender, and smoking status as control variables. 
In patients with schizophrenia, CPZ dose was also controlled. 
Plasma sTNFR2 levels were still found to be significantly and 
negatively correlated with hippocampal volume in all sam-
ples (patients with schizophrenia and healthy controls) and in 
patients with schizophrenia using a partial correlation analysis 
(total; n = 239, r = -0.26, P = 4.8 × 10–5, SCZ; n = 71, r = -0.27, P = .02).
To confirm the negative correlation between the plasma 
sTNFR2 levels and hippocampal volume, FreeSurfer analysis 
was also conducted. A  significant negative correlation between 
plasma sTNFR2 levels and left hippocampal volume measured 
by FreeSurfer analysis was observed in all samples (patients with 
schizophrenia and healthy controls) (total; n = 235, r = -0.16, P = .016, 
SCZ; n = 82, r = -0.19, P = .09, HC; n = 153, r = -0.04, P = .63). A  partial 
correlation using age, gender, and smoking status as control vari-
ables did not change the results (total; n = 214, r = -0.24, P = 4.3 × 10–4).
Table 3. Correlation between Plasma sTNFR2 Levels and Cognitive Function
Total Schizophrenia Healthy Control
n r P
Corrected  
P value n r P
Corrected  
P value n r P
Corrected  
P value
IQ WAIS VIQ 263 -0.19 2.4 × 10–3** .031* 87 0.14 n.s. n.s. 176 -0.19 .012* n.s.
PIQ 263 -0.21 8.1 × 10–4*** .011* 87 0.04 n.s. n.s. 176 -0.13 n.s. n.s.
FIQ 263 -0.22 3.5 × 10–4*** 4.5 × 10–3*** 87 0.09 n.s. n.s. 176 -0.19 .012* n.s.
VC 263 -0.16 .011* n.s. 87 0.16 n.s. n.s. 176 -0.19 .014* n.s.
PO 263 -0.2 1.5 × 10–3*** .019* 87 0.03 n.s. n.s. 176 -0.16 .036* n.s.
WM 260 -0.16 9.5 × 10–3** n.s. 84 0.08 n.s. n.s. 176 -0.15 .049* n.s.
PS 260 -0.2 1.0 × 10–3*** .013* 84 0.01 n.s. n.s. 176 -0.1 n.s. n.s.
Memory WMS VerM 267 -0.26 1.3 × 10–5*** 1.7 × 10–4*** 91 -0.02 n.s. n.s. 176 -0.15 .049* n.s.
ViM 267 -0.22 2.2 × 10–4*** 2.8 × 10–3*** 91 -0.13 n.s. n.s. 176 -0.13 n.s. n.s.
GM 267 -0.28 2.2 × 10–6*** 2.9 × 10–5*** 91 -0.06 n.s. n.s. 176 -0.16 .03* n.s.
A/C 267 -0.15 .018* n.s. 91 0.02 n.s. n.s. 176 -0.06 n.s. n.s.
DR 267 -0.26 2.2 × 10–5*** 2.9 × 10–4*** 91 -0.11 n.s. n.s. 176 -0.11 n.s. n.s.
AVLT total 
recall
257 -0.36 2.4 × 10–9*** 3.2 × 10–8*** 81 -0.23 .03* n.s. 176 -0.32 1.2 × 10–5*** 1.6 × 10–4***
*P < .05, **P < .01, ***P < .005
Abbreviations: A/C, Attention and Concentration; DR, delayed recall; FIQ, Full-scale IQ; GM, General Memory; n.s., not significant; VIQ, Verbal IQ; PIQ, Performance IQ; 
PO, Picture Completion Block Design and Matrix Reasoning; PS, Block Design and Matrix Reasoning; VerM, Verbal Memory; ViM, Visual Memory; WM, Airthmetic, Digit 
Span and Letter Number Sequencing. 
Figure 3. Correlation of the left hippocampus volume and plasma levels of sTNFR2 (a). sTNFR2 was negatively correlated with the left hippocampus volume. Anatomical 
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Correlation Between Clinical Variables and Plasma 
Level of sTNFR2
We also observed the correlations between clinical variables 
and plasma level of sTNFR2. PANSS positive subscale scores and 
duration of illness were positively and significantly correlated 
with plasma level of sTNFR2 (supplementary Table  5, PANSS-
positive; r = 0.23, P = .01, duration of illness; r = 0.35, P = 7.9 × 10–5). 
PANSS scores were also negatively and significantly correlated 
with many of cognitive functions (supplementary Table 5).
Discussion
In this study, we confirmed that the plasma levels of sTNFR2 
were significantly increased in patients with schizophrenia in 
a large Japanese cohort that include antipsychotic drugs-free 
patients and treatment-resistant patients. The involvement of 
inflammatory-related pathways, including TNF-α-related path-
ways, in schizophrenia has been implied by many studies (Dean 
et al., 2013). Our data showing higher plasma sTNFR2 levels in 
patients with schizophrenia are consistent with the results of 
previous studies (Coelho et  al., 2008; Noto et  al., 2013; Hoseth 
et  al., 2017). Many studies have shown that proinflammatory 
cytokines including TNF-α are etiological factors for schizo-
phrenia (Na et al., 2014). Considering the neuroprotective roles 
of sTNFR2, it is possible that high levels of sTNFR2 in schizo-
phrenia are the compensatory response to proinflammatory 
imbalance in the TNF system. To the best of our knowledge, 
this is the first study to demonstrate that plasma sTNFR2 levels 
are significantly increased in antipsychotic drugs-free patients 
with schizophrenia, suggesting that higher levels of sTNFR2 in 
patients with schizophrenia are not the result of medication. It 
has been reported that sTNFR1, but not sTNFR2, levels are higher 
in treatment-resistant patients than in controls (Noto et  al., 
2013). However, our results showed that sTNFR2 levels were also 
higher in treatment-resistant patients than in controls.
It has been reported that higher peripheral levels of sTNFR2 
are associated with worse cognitive function in community sam-
ples (Gao et al., 2016), Parkinson’s disease patients (Rocha et al., 
2014), and mood disorder patients (Doganavsargil-Baysal et al., 
2013; Bobińska et al., 2017). The plasma TNF-α/sTNFRs (sTNFR1 
and sTNFR2) ratio was also reported to be significantly associ-
ated with working memory assessed via the WAIS-III in patients 
with schizophrenia. However, an association between plasma 
sTNFR2 levels and cognitive function has not been investigated 
in patients with schizophrenia. We found that higher plasma 
sTNFR2 levels were associated with worse cognitive function. 
A  significant association was observed mainly in all samples 
(patients with schizophrenia and healthy controls), and we did 
not detect a significant association in patients with schizophre-
nia only. The effect of sTNFR2 on cognitive function might be the 
indirect one in the pathophysiology of schizophrenia. Most sub-
categories of both the WAIS and WMS-R were associated with 
plasma sTNFR2 levels, suggesting that sTNFR2 is associated with 
general cognitive and memory functions rather than specific 
functions.
Higher peripheral sTNFR2 levels were reported to be associ-
ated with smaller hippocampal volume in a community sample 
(Schmidt et al., 2016). However, an association between periph-
eral sTNFR2 levels and hippocampal volume in patients with 
schizophrenia has not yet been investigated. An association 
between the plasma levels of sTNFR1 and hippocampal volume 
was investigated in patients with schizophrenia, and no signifi-
cant association was observed (Hoseth et al., 2016). We found the 
significant negative association between plasma level of sTNFR2 
and hippocampal volume in patients with schizophrenia at least 
in VBM analysis. Although we found significant negative correla-
tion of sTNFR2 levels and cognition mainly in healthy controls, a 
significant correlation of sTNFR2 levels and hippocampal volume 
was observed mainly in patients with schizophrenia, and we did 
not detect a significant association in healthy controls only. The 
results showing discrepancy between cognition and brain vol-
ume. It is possible that sTNFR2 levels have a more direct effect 
on hippocampal volume than cognition in pathophysiology of 
schizophrenia. Experimental data suggest that administration 
of TNF-α attenuate hippocampal growth (Seguin et  al., 2009), 
whereas depletion of sTNFR2 lead to hippocampal neuron death 
(Yang et al., 2002). It is possible that sTNFR2 play protective roles 
in hippocampus against activation of TNF system that could 
potentially contribute to a decrease in hippocampal volume.
The results of this study should be evaluated in light of cer-
tain limitations. First, plasma sampling conditions, such as the 
time of sampling and diet, might modulate the plasma levels 
of investigated markers. However, these conditions were not 
controlled for in this study. In addition, sTNFRs (sTNFR1 and 
sTMFR2) have been reported to be correlated with body mass 
index (BMI) (Hinze-Selch et al., 2000; Himmerich et al., 2006), and 
this association indicates that BMI should be controlled for in 
such studies. However, the BMI of our subjects was not available 
and was therefore not controlled for in this study.
The results that increased plasma sTNFR2 levels are associ-
ated with a smaller hippocampal volume and cognitive impair-
ment in schizophrenia suggest that sTNFR2 might play an 
important role in the pathophysiology in schizophrenia. Further 
studies are needed to elucidate the mechanism how sTNFR2 in 
schizophrenia have effect on hippocampal volume loss and cog-
nitive impairment.
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Supplementary data are available at International Journal of 
Neuropsychopharmacology online.
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